Agenus Inc. (AGEN) Stock Price

AGENStock

$6.04+51.38%52W

Market Cap$272.78M

P/E2371.98x

PEG Ratio1.44

Div yield—

Beta1.53

AGEN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)18.06%

Price vs S&P 500 (4W)-26.17%

PEG Ratio1.44

VGM Score68.63

P/E Ratio (Annual)2371.98x

Book Value / Share (Quarterly)$0.24

P/TBV (Annual)31.87x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)5.22%

Cash Flow / Share (Quarterly)$-2.31

Price vs S&P 500 (YTD)80.43%

Gross Margin (TTM)99.52%

Net Profit Margin (TTM)69.34%

EPS (TTM)$2.65

10-Day Avg Trading Volume1.00M

EPS Excl Extra (TTM)$2.65

Revenue Growth (5Y)5.31%

EPS (Annual)$0.00

ROI (Annual)-49.19%

Gross Margin (Annual)99.11%

Net Profit Margin (5Y Avg)-121.87%

Cash / Share (Quarterly)$0.44

P/E Basic Excl Extra (TTM)2.96x

Revenue Growth QoQ (YoY)34.36%

P/E Normalized (Annual)2371.98x

ROA (Last FY)0.05%

Revenue Growth TTM (YoY)30.47%

EBITD / Share (TTM)$3.86

ROE (5Y Avg)-132.67%

Operating Margin (TTM)103.19%

Cash Flow / Share (Annual)$-2.19

P/B Ratio79.85x

P/B Ratio (Quarterly)153.49x

Net Income / Employee (Annual)$1,400

EV / Revenue (TTM)4.02x

Net Interest Coverage (TTM)0.96x

ROA (TTM)44.89%

EV / EBITDA (TTM)3.77x

EPS Incl Extra (Annual)$0.00

Current Ratio (Annual)0.41x

Quick Ratio (Quarterly)0.33x

3-Month Avg Trading Volume3.30M

52-Week Price Return51.38%

P/E Incl Extra (TTM)2.96x

Revenue / Employee (TTM)$1,638,200

Tangible BV / Share (Quarterly)$0.60

P/S Ratio (Annual)2.39x

Asset Turnover (Annual)0.50x

52-Week High$10.31

Operating Margin (5Y Avg)-64.44%

EPS Excl Extra (Annual)$0.00

CapEx CAGR (5Y)-71.97%

Tangible BV CAGR (5Y)-23.22%

26-Week Price Return27.97%

Quick Ratio (Annual)0.41x

13-Week Price Return20.56%

Total Debt / Equity (Annual)0.41x

Current Ratio (Quarterly)0.34x

Enterprise Value$533.57M

Revenue / Share Growth (5Y)-17.78%

Asset Turnover (TTM)0.65x

Book Value / Share Growth (5Y)-61.57%

Revenue / Employee (Annual)$1,409,800

Inventory Turnover (Annual)0.00x

Pretax Margin (Annual)-2.70%

Cash / Share (Annual)$0.08

3-Month Return Std Dev99.57%

Gross Margin (5Y Avg)96.94%

Net Income / Employee (TTM)$1,136,000

ROE (Last FY)-69.47%

Net Interest Coverage (Annual)2.10x

EPS Basic Excl Extra (Annual)$0.00

P/FCF (TTM)2.50x

Receivables Turnover (TTM)17.19x

Total Debt / Equity (Quarterly)4.01x

EPS Incl Extra (TTM)$2.65

Receivables Turnover (Annual)102.05x

ROI (TTM)48.69%

P/S Ratio (TTM)2.06x

Pretax Margin (5Y Avg)-127.38%

Revenue / Share (Annual)$3.84

Tangible BV / Share (Annual)$2.02

Forward P/E149.10x

Price vs S&P 500 (52W)35.85%

P/E Ratio (TTM)2.96x

Year-to-Date Return92.36%

5-Day Price Return-18.71%

EPS Normalized (Annual)$0.00

ROA (5Y Avg)-47.40%

Net Profit Margin (Annual)0.10%

Month-to-Date Return-39.17%

Cash Flow / Share (TTM)$-0.81

EBITD / Share (Annual)$3.05

Operating Margin (Annual)70.54%

LT Debt / Equity (Annual)0.37x

ROI (5Y Avg)-75.46%

P/E Excl Extra (TTM)2.96x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$2.65

P/TBV (Quarterly)79.78x

P/B Ratio (Annual)24.02x

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)69.29%

Book Value / Share (Annual)$2.68

Price vs S&P 500 (13W)17.87%

Beta1.53x

P/FCF (Annual)299.76x

Revenue / Share (TTM)$3.21

ROE (TTM)76.63%

52-Week Low$2.71

vGradeB

gGradeB

mGradeB

vgmGradeB

AGEN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 7, 2026	$0.04	-$0.01	-125.00%(-$0.05)
Q1 2026	May 11, 2026	$1.80	-$0.03	-101.77%(-$1.83)
Q4 2025	Mar 16, 2026	-$1.30	$0.68	+152.37%(+$1.98)
Q3 2025	Nov 10, 2025	$2.20	-$1.16	-152.92%(-$3.36)
Q2 2025	Aug 11, 2025	$1.35	-$1.00	-173.89%(-$2.35)

AGEN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.13

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
AGENAgenus Inc.	B	B	B	2.1x	30.5%	99.5%	—	$6.04
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Agenus Inc.

Agenus is a clinical-stage immunotherapy company developing therapies to activate the immune system against cancer and infectious disease. Its pipeline includes immune-modulatory antibodies (botensilimab, a CTLA-4 inhibitor; balstilimab, a PD-1 inhibitor), adoptive cell therapies through subsidiary MiNK Therapeutics, and vaccine adjuvants via subsidiary SaponiQx. The company operates in-house cGMP manufacturing and clinical operations capabilities to support product development.